Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Annaly Capital Management, Inc. (NLY): Can This Mortgage REIT Outmaneuver the Fed?

The behavior of the Federal Reserve has weighed heavily on the shoulders of mortagage REITs like American Capital Agency Corp. (NASDAQ:AGNC) and Annaly Capital Management, Inc. (NYSE:NLY) as the government continues to scoop up the very same mortgage-backed securities backed by Fannie and Freddie that these companies also covet.

However, while the open-ended MBS buying spree has had a deleterious effect on the interest margin spread of both of these mREITs, Annaly’s current spread of 0.95% looks meager compared to American Capital Agency’s healthier 1.63%. In the earnings call released after its fourth-quarter earnings report, the company gives some details on just how it has been able to cope with the recent actions of the Fed — and how QE3 has actually helped American Capital Agency’s ability to keep that spread so wide.

Annaly Capital Management, Inc. (NYSE:NLY)New financing opportunities with QE3
The Fed’s heavy involvement in the agency MBS market has opened up new avenues for financing through the TBA (“to be announced”) dollar roll market, and American Capital Agency has jumped in with gusto. Management noted that terms have been much kinder to the company here than in the repurchase agreement market.

As the company notes, selling and then agreeing to buy back a comparable security at a later date provides a nice price drop for the buyer. To illustrate, management gave the example of a 30-year, 3% TBA MBS where the price drop as of December was $0.24 — the difference between a January settlement and a February settlement. This dollar amount translates into a financing rate that the repo market simply can’t beat.

The beauty of this situation, of course, is that it is as open-ended as QE3 — and is apt to continue through the rest of this year. Since it translates into savings for the company, American Capital Agency’s management can’t resist taking advantage. To boot, the terms have become even more favorable in the first quarter of 2013 than they were last quarter.

What about Annaly?
American Capital Agency’s management seems so enamored of the TBA market that it makes me wonder why others, namely Annaly, don’t participate. While it is possible that it does, and just doesn’t talk about it, that paltry spread convinces me that this is not the case.

Not that Annaly is sitting on its hands. It has taken steps to relieve its spread compression, most notably the bid to purchase the remaining shares of Crexus Investment Corp (NYSE:CXS), which invests in commercial MBSes. Indeed, Annaly’s CEO recently commented that, with the power of Annaly’s balance sheet, CreXus could present a “spectrum of opportunity,” that could well be “exponential.”

Both of these mREITs are coping with Fed behavior in the current environment, while trying to predict future actions, as well. But, that special brand of shrewdness is precisely — as American Capital Agency’s CIO Gary Kain says — what investors are paying management for.

The article Can This Mortgage REIT Outmaneuver the Fed? originally appeared on and is written by Amanda Alix.

Fool contributor Amanda Alix has no position in any stocks mentioned. The Motley Fool owns shares of Annaly Capital Management.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!